What Strensiq Treats: Main Uses and Benefits

Strensiq is commonly used in the management of Hypophosphatasia (HPP), specifically for perinatal/infantile- and juvenile-onset forms. This therapy is applied to help manage the severe, chronic symptoms associated with this rare genetic condition.

The therapeutic benefit is relevant for easing symptoms that create noticeable physiological strain across three main areas: skeletal problems, physical function, and systemic manifestations. Clinically, it is relevant in contexts involving pronounced discomfort and is applied when additional supportive symptom management is needed to address symptom clusters such as painful skeletal deformities and impaired motor skills.

“This medication may assist with managing symptom clusters that interfere with daily comfort and is often used during phases when symptoms become more noticeable.”

Quick Fact: Relief for Skeletal Pain and Impaired Mobility

By supporting the skeletal system, the treatment may assist with easing the overall symptom load of bone pain and maintaining functional stability. This supports patients during difficult episodes, which may assist with maintaining functional stability during daily activities.

Regulatory References

1. FDA Prescribing Information on DailyMed

Eligibility Map: Who Can and Cannot Use Strensiq — Official Regulatory Information

The eligibility for Strensiq (asfotase alfa) is strictly defined by regulatory bodies based on disease onset and patient history.

---

Eligibility Scope	Official Regulatory Status
Populations for whom use is allowed	Patients with perinatal/infantile-onset or juvenile-onset hypophosphatasia (HPP) are indicated for treatment.
Populations for whom use is contraindicated	The medicine is contraindicated in patients with a history of severe or life-threatening systemic hypersensitivity to asfotase alfa.
Age-related eligibility rules	The medicine is indicated for paediatric-onset HPP across all ages (infants through adolescents). Data in patients over 65 years old is limited.
Pregnancy and lactation eligibility status	Use during pregnancy is not recommended due to insufficient data; if used, the potential benefit must outweigh the risk. It is also not recommended for women who are breastfeeding.
Condition-specific eligibility rules	Safety and efficacy have not been evaluated in patients with significant renal or hepatic impairment, and no specific regimen is recommended.
Eligibility-related restrictions	Use has not been established for patients with mild HPP that manifests only as dental findings (odontohypophosphatasia).

---

Official regulatory documents strictly define who can and cannot use Strensiq primarily by the specific onset of hypophosphatasia and the patient's immunological history. Use is explicitly contraindicated based on a history of severe hypersensitivity, and strict limitations are established for groups where data is insufficient, such as in patients with renal or hepatic impairment.

Interactions with other medicines and products

The official regulatory profile for Strensiq (asfotase alfa) is highly specific, being primarily defined by the absence of typical drug-drug interactions and the presence of a key procedural constraint. As a recombinant fusion protein, Strensiq is unlikely to affect the metabolism of co-administered medicines. Regulatory authorities state that, based on its unique structure and pharmacokinetics, no significant interactions with the Cytochrome P-450 (CYP) enzyme system are expected. Therefore, no exposure-modifying effects on other drugs are officially documented. Furthermore, official labeling indicates no documented interactions with food, alcohol, or herbal products, and no mandatory timing-based separation rules are mandated for co-administration.

Official Interaction Constraint

The single, officially documented interaction is classified as Drug Interference with Laboratory Tests. This constraint arises because Alkaline Phosphatase (ALP) is often used as a detection reagent in many clinical laboratory assays. The presence of Strensiq in clinical samples can interfere with these ALP-conjugated test systems, potentially resulting in erroneous test results for various analytes under investigation.

Classification	Official Regulatory Status
Contraindicated Combinations	None documented with other medicines or substances.
Metabolic/PK Interactions	Unlikely to affect CYP-related metabolism.
Documented Constraint	Interference with specific laboratory products/reagents.

This profile confirms that the medicine does not engage in common pharmacokinetic pathways; therefore, the only constraint is a procedural necessity for accurate laboratory test interpretation.

How Strensiq Works

Strensiq (asfotase alfa) is a bone-targeted enzyme replacement therapy that addresses the deficiency of the tissue-nonspecific alkaline phosphatase (TNSALP) enzyme. This action directly restores the necessary enzymatic activity to process excess accumulated substrates: pyrophosphate (PPi), pyridoxal-5′-phosphate (PLP), and phosphorylethanolamine (PEA).

---

Pyrophosphate Hydrolysis and Mineralization Correction

This effect centers on the enzyme's role in hydrolyzing PPi into inorganic phosphate (Pi). By reducing the excess PPi concentration, the drug alleviates the inhibition of mineralization, facilitating the calcification of bone and cartilage. This foundational physiological correction is necessary for proper skeletal matrix formation.

---

Regulation of B6 Metabolism

This pathway addresses the enzyme’s secondary role in cleaving excess PLP. Re-establishing this proper metabolic pathway helps to normalize the elevated levels of PLP. Normalization of elevated PLP levels limits the impact of metabolite dysregulation on the central nervous system. This mechanistic domain contributes to the overall pharmacodynamic effect.

Strensiq (asfotase alfa) is administered solely by subcutaneous injection and is intended for long-term management. The initiation of therapy should be supervised by a physician experienced in treating metabolic or bone disorders.

---

Dosing Regimen

The dosage is strictly weight-based, calculated at a standard dose of 6 mg/kg of body weight per week. This total weekly amount is divided into one of two schedules: 2 mg/kg three times per week, or 1 mg/kg six times per week (daily). The dose must be periodically adjusted as the patient’s weight changes. For patients with perinatal/infantile-onset HPP who show insufficient response, the dose may be increased up to a maximum of 9 mg/kg per week. If a dose is missed, a double dose should not be injected to compensate for the omission.

---

Administration Conditions

Specific conditions govern the proper administration of the injection. Before use, the single-dose vial should be removed from refrigeration and allowed to warm to room temperature for 15 to 30 minutes. To help minimize injection site reactions, sites must be rotated. A key procedural constraint is the maximum volume per single injection site, which must not exceed 1 mL. If the patient's calculated dose requires a volume greater than this, the dose must be split equally and administered across multiple, separate injection sites. Furthermore, the 80 mg/0.8 mL vial is not recommended for pediatric patients weighing less than 40 kg.

Research evidence / Overview of studies for Strensiq

The research foundation for Strensiq (asfotase alfa) is primarily based on open-label clinical trials and long-term observational studies. The research examined measured outcomes related to skeletal and functional status across different age groups.

---

Evidence for Use in Perinatal/Infantile-Onset Hypophosphatasia

Researchers studied the effect of Strensiq in infants and young children whose symptoms appeared before six months of age. The outcomes that research examined included changes in overall survival and ventilator-free survival, as well as skeletal healing assessed using standardized radiographic tools (RGI-C and RSS).

What remains uncertain is related primarily to the research design itself. The evidence is derived from studies with small patient numbers. More importantly, the initial evidence lacks a contemporary, prospectively randomized control group. This reliance means the certainty remains low for some of the findings.

---

Evidence for Use in Juvenile-Onset Hypophosphatasia

The research exploring the use of Strensiq in juvenile-onset HPP is primarily composed of open-label studies and subsequent long-term extension trials. The outcomes examined focused on physical and motor function, often measured by the Six-Minute Walk Test (6MWT), as well as skeletal manifestations, and tracked patient-reported outcomes.

Certainty remains low due to the continued reliance on small patient numbers and the single-arm study design. Comparative evidence is lacking for many functional outcomes because most studies did not include a concurrent, untreated group.

---

Long-Term Research and Follow-up Data

Given that HPP is a lifelong condition, long-term extension studies and observational registries track patients over extended periods in real-world settings. This research describes patterns related to the long-term status of the initial observed changes in both skeletal and functional status metrics. While these multi-year studies are valuable, long-term effects are not fully established beyond the observed follow-up periods.

---

Study Populations and Subgroups Evaluated

The clinical research for Strensiq has included a wide age range, from infants to adults. The populations were primarily categorized by the age of HPP onset. Studies explored outcomes in children and adolescents, focusing on growth and motor skills, as well as adults who had experienced pediatric-onset HPP.

Subgroup findings are uncertain for adults who began treatment during adulthood, as most long-term data reflects patients who started treatment earlier in life. Furthermore, there is limited information regarding the use of Strensiq in certain special populations, such as pregnant or lactating women.

---

What is Still Uncertain About the Research

It is important to understand the limitations of the evidence for any medicine, particularly for a rare disease. A primary limitation is that most pivotal studies included small sample sizes, which makes generalizing findings to the entire patient population challenging. Furthermore, the early research often relied on historical controls, rather than a concurrent randomized control group. This design contributes to the uncertainty in the evidence base. Research does not provide individual predictions of a patient’s outcome.

Key Studies & References STRENSIQ (asfotase alfa) injection, for subcutaneous use - FDA Prescribing Information

Common questions about Strensiq (FAQ)

Q: How long does it typically take to see benefits from Strensiq?

Studies and official information indicate that patients with infantile and juvenile-onset HPP showed sustained improvements in bone mineralization and growth starting from approximately six months after initiating treatment. However, the exact time it takes to see benefits can vary significantly between individuals.

---

Q: What are the most commonly reported side effects of Strensiq?

According to official regulatory documents, the most common side effects reported in clinical trials (occurring in 10% or more of patients) include injection site reactions (such as redness or pain), lipodystrophy (changes in fat tissue structure at the injection site), ectopic calcifications (mineral deposits in soft tissues), and hypersensitivity reactions.

---

Q: Can Strensiq cause injection site reactions, and what do they look like?

Yes, injection site reactions are a very common side effect. These reactions may include redness (erythema), pain, itching (pruritus), rash, papules, nodules, or discoloration at the injection area. Rotating the injection sites is recommended to help minimize these local reactions.

---

Q: What happens if I miss a scheduled dose of Strensiq?

Regulatory guidance suggests patients resume the regular schedule as soon as possible if a dose is missed. It is very important that the total weekly dose not be doubled to compensate for the omitted injection. Further scheduling questions should be directed to the prescribing healthcare professional.

---

Q: Can taking Strensiq impact the effectiveness of common pain relievers?

Strensiq is a biologic protein that is not expected to interfere with the body's main system for metabolizing other drugs (the CYP enzyme system). Official labeling states that no significant interactions with common pain relievers are officially expected or documented.

---

Q: Are there specific diet restrictions needed while on Strensiq?

According to official regulatory labeling, no documented interactions with food or alcohol have been established. There are no mandatory timing rules regarding when you must take your medication in relation to meals.

---

Q: Can Strensiq affect vision or cause eye problems?

Yes, official safety information notes that HPP patients treated with Strensiq have reported ophthalmic issues, specifically calcification in the conjunctiva and cornea of the eye. Monitoring for these issues is a standard precaution, and regular eye checks are noted in official prescribing information.

---

Q: Do patients need regular lab work or monitoring while taking Strensiq?

Regular monitoring is needed to check for serious adverse events like ectopic calcifications (especially in the eyes and kidneys) and Craniosynostosis (in children under 5 years old). The drug also interferes with routine laboratory measurements of serum Alkaline Phosphatase (ALP), which requires special consideration when interpreting blood test results.

---

Q: What were the key findings from the clinical trials for Strensiq?

Clinical trial results indicated significant improvements in key areas for HPP patients. Key findings include increased skeletal healing and better scores on physical function tests for juvenile patients, as well as improved overall survival and ventilator-free survival rates for infants with perinatal or infantile onset HPP.

---

Q: What is still uncertain about the research?

Official regulatory reviews highlight several limitations in the evidence base. These include the generally small number of patients enrolled in pivotal studies and the initial reliance on historical controls rather than a contemporary randomized control group. Additionally, the long-term effects of the medicine are still not fully established beyond the specific follow-up periods observed in the studies.

---

Q: Is Strensiq a cure for hypophosphatasia (HPP)?

Strensiq is officially defined as an enzyme replacement therapy used for the long-term treatment of the bone manifestations of HPP. Regulatory documents define its role as a therapy that addresses the underlying cause of the disease, not as a cure.

---

Q: How does Strensiq treatment differ from standard treatments for HPP?

Strensiq is classified as a first-in-class enzyme replacement therapy (ERT) for HPP. Its mechanism is different from that of supportive treatments because it directly replaces the deficient enzyme (TNSALP) needed for proper bone mineralization.

---

Q: What does Strensiq do to bones and teeth?

Strensiq works to promote bone mineralization. It breaks down a substance called inorganic pyrophosphate (PPi), which otherwise prevents the deposition of essential minerals. This physiological correction is necessary for proper skeletal matrix and tooth structure formation, and the drug is indicated for treating the bone manifestations of HPP.

---

Q: Are the effects of Strensiq permanent, or does the treatment need to continue indefinitely?

According to official regulatory documents, Strensiq is indicated for long-term enzyme replacement therapy, suggesting the need for continued treatment to maintain the benefits.

---

Q: Are there any serious or rare side effects associated with Strensiq that I should know about?

Official labeling documents the potential for serious events, including severe and potentially life-threatening hypersensitivity reactions (such as Anaphylaxis). Also, Craniosynostosis (premature fusion of skull sutures) has been reported in children under 5 years of age. Patients are monitored for signs of these serious events.

---

Q: What are the steps for proper self-injection of Strensiq?

Strensiq is administered strictly by subcutaneous injection. A key requirement is that the dose must be split and administered across multiple, separate injection sites if the volume exceeds 1 mL for a single spot. Injection sites must be rotated. Detailed, step-by-step instructions are provided in the Patient Instructions for Use (PIFU) and are reviewed by a healthcare professional.

---

Q: Can Strensiq be administered in places other than the thigh or abdomen?

Yes. While the thigh and abdomen are common sites, official patient instruction materials also list the buttocks and the upper arm as suitable areas for subcutaneous injection. It is essential to rotate sites to prevent injection site reactions.

---

Q: Are there different forms of HPP that Strensiq is approved to treat?

Official regulatory indications specify that Strensiq is approved for the treatment of patients with perinatal/infantile-onset and juvenile-onset hypophosphatasia (HPP).

---

Q: Does Strensiq treat all symptoms of HPP, or just the skeletal ones?

Strensiq is primarily indicated to treat the bone manifestations of HPP. However, the drug’s mechanism of action, which normalizes levels of the metabolite PLP, also helps limit the impact of metabolic dysregulation on the central nervous system.

---

Q: Is Strensiq considered a long-term or short-term treatment option?

Strensiq is officially designated as a long-term enzyme replacement therapy for HPP.

---

Q: Are there special considerations for travel when using Strensiq?

Yes. Strensiq requires continuous refrigeration (between 2 C and 8 C / 36 F and 46 F) and must never be frozen. Special care and planning, including calculating the supplies needed, are required to maintain the cold chain during travel.

---

Q: Is Strensiq related to other treatments for metabolic disorders?

Strensiq is a first-in-class enzyme replacement therapy (ERT) for HPP, a specific metabolic bone disorder. This pharmacological class and mechanism are similar to other ERTs used to address different enzyme deficiencies found in rare metabolic conditions.

---

Q: What is the average duration of treatment with Strensiq?

Official regulatory documents indicate that Strensiq is prescribed for long-term enzyme replacement therapy.

---

Q: How quickly does Strensiq degrade or expire after opening the vial?

Strensiq is supplied in single-use vials. Once the unopened vial is removed from the refrigerator and warmed to room temperature, it must be used within 3 hours. Any portion remaining in the vial after administration must be immediately discarded.

---

Q: Is it possible to become resistant to the effects of Strensiq over time?

Clinical trials reported that most patients developed antibodies to the drug, which has been linked to a reduced systemic exposure. Patients are monitored for any signs of worsening symptoms or potential immune-mediated clinical effects.

---

Q: What kind of specialist typically prescribes and manages Strensiq therapy?

Treatment should be initiated and managed by a physician who is experienced in treating metabolic or bone disorders, as outlined in the official prescribing information.

---

Q: Does Strensiq help with the pain associated with HPP?

Official studies focused on its effect on skeletal healing and functional improvement (e.g., walking ability). While pain relief is not a specific stated indication, studies for juvenile-onset HPP did track patient-reported outcomes, which may include pain as an overall measure of improvement.

---

Q: What are the signs that Strensiq might be working for a patient with HPP?

Clinical trial results showed evidence of efficacy through increased skeletal healing (visible on X-rays) and improvements in physical function and height growth in children. These objective outcomes are the general signs that indicate a benefit is being achieved.

---

Q: Can Strensiq cause changes in mood or sleep patterns?

Official safety labeling notes irritability as a very common side effect in patients. While not specifically listing changes in sleep or mood as common events, central nervous system-related symptoms like headache are also reported in the overall patient experience.

How to Store and Dispose of STRENSIQ (asfotase alfa)

STRENSIQ must be stored refrigerated between 2°C and 8°C (36°F and 46°F) and kept in its original carton to protect it from light. The vials must not be frozen; discard any product suspected of freezing. It is required to keep the medicine out of the reach of children.

---

Stability and Handling

STRENSIQ is supplied in single-use vials. The drug must not be shaken. After removal from the refrigerator, the unopened vial should be allowed to warm up at room temperature for 15 to 30 minutes, but must be used within 3 hours.

---

Disposal

Any unused portion remaining in the vial must be discarded. Used needles and syringes must be placed immediately in an FDA-cleared sharps disposal container and disposed of according to local regulations. Sharps waste must not be placed in household trash.